This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis
by Zacks Equity Research
SFM, RGLD, TRI, WWD and EXEL are non-tech Nasdaq standouts with strong ranks, rising estimates and double-digit gains in 2025.
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
by Zacks Equity Research
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
by Zacks Equity Research
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
by Zacks Equity Research
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2
by Nalak Das
Nasdaq is flat in first-half 2025, but SFM, RGLD, TRI, WWD and EXEL are soaring, each up over 20% and primed for the second half.
SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma
by Zacks Equity Research
Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
by Zacks Equity Research
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
by Zacks Equity Research
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane
by Zacks Equity Research
BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.
Here's Why Exelixis (EXEL) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or ARGX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis
by Zacks Equity Research
FLEX, CVS, URBN and EXEL stand out as GARP picks with strong growth outlooks and discounted PEG ratios.
4 Attractive GARP Picks for Your Portfolio Based on PEG Ratio
by Urmimala Biswas
Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)
by Ethan Feller
Palomar Holdings, Exelixis and Olo stocks all boast top Zacks Ranks, reasonable valuations and strong price momentum
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
by Zacks Equity Research
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice
by Zacks Equity Research
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
by Zacks Equity Research
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Urban Outfitters (URBN), Tenet Healthcare (THC), Five9 (FIVN), Marqeta (MQ) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.